Artal Group’s BridgeBio Pharma BBIO Stock Holding History

Artal Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500,000	Closed	-$8.29M	–	122
2023 Q1	$8.29M	Buy	500,000 +250,000	+100%	+$2.92M	0.49%	46
2022 Q4	$1.91M	Hold	250,000	–	–	0.11%	90
2022 Q3	$2.48M	Hold	250,000	–	–	0.11%	82
2022 Q2	$2.27M	Hold	250,000	–	–	0.12%	90
2022 Q1	$2.54M	Hold	250,000	–	–	0.11%	108
2021 Q4	$4.17M	Hold	250,000	–	–	0.11%	111
2021 Q3	$11.7M	Sell	250,000 -25,000	-9%	-$1.34M	0.26%	72
2021 Q2	$16.8M	Buy	275,000 +25,000	+10%	+$1.43M	0.34%	62
2021 Q1	$15.4M	Sell	250,000 -50,000	-17%	-$3.27M	0.27%	77
2020 Q4	$21.3M	Sell	300,000 -100,000	-25%	-$4.82M	0.46%	57
2020 Q3	$15M	Sell	400,000 -200,000	-33%	-$6.29M	0.36%	57
2020 Q2	$19.6M	Buy	600,000 +50,000	+9%	+$1.52M	0.55%	43
2020 Q1	$15.9M	Buy	550,000 +350,000	+175%	+$10.9M	0.67%	35
2019 Q4	$7.01M	Hold	200,000	–	–	0.27%	62
2019 Q3	$4.29M	Hold	200,000	–	–	0.17%	77
2019 Q2	$5.39M	Buy	+200,000	New	+$5.45M	0.22%	76

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Artal Group's BBIO Position: Q2 2023 in Review

Artal Group sold out of BridgeBio Pharma (BBIO) in Q2 2023, closing a stake of 500,000 shares — an estimated $8.29M sold.

Artal Group first reported a position in BBIO in Q2 2019 and held it in 16 quarters. The position peaked at $21.3M in Q4 2020. 197 funds tracked by Wall St. Rank hold BBIO as of Q2 2023.

Artal Group reported no remaining BridgeBio Pharma position as of Q2 2023 after selling out during the quarter.
Artal Group sold 500,000 BridgeBio Pharma shares in Q2 2023, an estimated $8.29M.
Artal Group first reported a position in BridgeBio Pharma in Q2 2019 and held it in 16 quarters.
Artal Group's BridgeBio Pharma position peaked at $21.3M in Q4 2020.
197 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2023.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.